Synergistic effects of pesticides and metals on the fibrillation of α-synuclein: Implications for Parkinson's disease

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 527-536

  Uversky, Vladimir N ^a   Li, Jie ^a   Bower, Kiowa ^a   Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Synuclein; Aggregation; Fibrils; Metals; Pesticides

Indexed keywords

ALPHA SYNUCLEIN; METAL; PESTICIDE; ALUMINUM CHLORIDE; ALUMINUM DERIVATIVE; CHLORIDE; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CORRELATION ANALYSIS; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; GENETIC PREDISPOSITION; IN VITRO STUDY; LEWY BODY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; TIME SERIES ANALYSIS; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CIRCULAR DICHROISM; DIFFUSE LEWY BODY DISEASE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PATHOLOGY; SPECTROFLUOROMETRY;

ALPHA-SYNUCLEIN; ALUMINUM COMPOUNDS; CHLORIDES; CIRCULAR DICHROISM; DRUG SYNERGISM; HUMANS; LEWY BODY DISEASE; METALS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PESTICIDES; PROTEIN CONFORMATION; SPECTROMETRY, FLUORESCENCE; SYNUCLEINS;

EID: 0036777847     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00067-0     Document Type: Conference Paper

References (39)

1. Altschuler E. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med Hypotheses 1999;53:22-3.
2. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318-20.
3. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury Jr, PT. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000;97:571-6[in process citation].
4. Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Lett 1998;436:309-12.
5. 53) to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Lett 1998;440:67-70.
6. Eliezer D, Kutluay E, Bussell Jr, R, Browne G. Conformational properties of α-synuclein in its free and lipid-associated states. J Mol Biol 2001;307:1061-73.
7. Fink AL, Calciano LJ, Goto Y, Kurotsu T, Palleros DR. Classification of acid denaturation of proteins - intermediates and unfolded states. Biochemistry 1994;33:12504-11.
8. Fink AL, Oberg KA, Seshadri S. Discrete intermediates versus molten globule models for protein folding: characterization of partially folded intermediates of apomyoglobin. Fold Des 1998;3:19-25.
9. Goedert M. Parkinson's disease and other α-synucleinopathies. Clin Chem Lab Med 2001;39:308-12.
10. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-6.
11. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999;20:239-47.
12. Goto Y, Calciano LJ, Fink AL. Acid-induced folding of proteins. Proc Natl Acad Sci USA 1990a;87:573-7.
13. Goto Y, Takahashi N, Fink AL. Mechanism of acid-induced folding of proteins. Biochemistry 1990b;29:3480-8.
14. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res 1998;799:301-6.
15. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport 1999;10:717-21.
16. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. β-Synuclein inhibits α-synuclein aggregation. A possible role as an anti-Parkinsonian factor. Neuron 2001;32:213-23.
17. Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G. Diet and Parkinson's disease. II. A possible role for the past intake of specific nutrients. Results from a self-administered foodfrequency questionnaire in a case-control study. Neurology 1996;47:644-50[see comments].
18. Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 1994;9:69-75.
19. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991;56:446-51.
20. Iwatsubo T, Yamaguchi H, Fujimuro M, Yokosawa H, Ihara Y, Trojanowski JQ, Lee VMY. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am J Pathol 1996;148:1517-29.
21. Jakes R, Crowther RA, Lee VM, Trojanowski JQ, Iwatsubo T, Goedert M. Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein. Neurosci Lett 1999;269:13-6.
22. Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 2001;40:11604-13.
23. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice. Paraquat and α-synuclein. J Biol Chem 2002a;277:1641-4.
24. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice. Paraquat and α-synuclein. J Biol Chem 2002b;277:1641-4.
25. 1. Anal Biochem 1989;177:244-9.
26. Naiki H, Higuchi K, Matsushima K, Shimada A, Chen WH, Hosokawa M, Takeda T. Fluorometric examination of tissue amyloid fibrils in murine senile amyloidosis: use of the fluorescent indicator, thioflavine T. Lab Invest 1990;62:768-73.
27. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 1999;274:9843-6.
28. Shi L, Palleros DR, Fink AL. Protein conformational changes induced by 1,1′-bis(4-anilino-5-naphthalenesulfonic acid) - preferential binding to the molten globule of dnak. Biochemistry 1994;33:7536-46.
29. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73.
30. Tanner CM. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci 1989;12:49-54.
31. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.
32. Uversky VN, Karnoup AS, Segel DJ, Seshadri S, Doniach S, Fink AL. Anion-induced folding of staphylococcal nuclease: characterization of multiple equilibrium partially folded intermediates. J Mol Biol 1998;278:879-94.
33. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 2000;41:415-27.
34. Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ. Stabilization of partially folded conformation during α-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 2001a;276:43495-8.
35. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in α-synuclein fibril formation. J Biol Chem 2001b;276:10737-44.
36. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem 2001c;276:44284-96.
37. Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 2001d;500:105-8.
38. Weinreb PH, Zhen WG, Poon AW, Conway KA, Lansbury Jr, PT. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996;35:13709-15.
39. Yasui M, Kihira T, Ota K. Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 1992;13:593-600.